Optogenetics restores some vision in retinitis pigmentosa trial — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Retinitis pigmentosa is a genetic disorder that degenerates the retina's light-sensing cells; patients are typically diagnosed in childhood or early adolescence and often become legally blind by young adulthood.
- No cure exists for retinitis pigmentosa except for a subset of patients carrying a specific genetic mutation treatable with gene therapy; the rest receive only measures to slow degeneration and preserve remaining sight.
- Optogenetics — the technology recently recognized with a Nobel Prize — may offer hope for retinitis pigmentosa patients, according to a new paper published Wednesday in the New England Journal of Medicine.
- The newly published trial was small in scale and showed optogenetics partially restoring some vision lost to the disease, though the full clinical details remain behind STAT+'s paywall.
- The Nobel-recognized optogenetics technology works by making remaining retinal cells responsive to light, a mechanism distinct from the gene-therapy approach that only helps patients with one specific mutation.
Why it matters: Most retinitis pigmentosa patients have zero disease-modifying treatment options today; this small optogenetics trial, published alongside a Nobel Prize for the underlying technology, marks one of the first reported cases of partial vision restoration in non-gene-therapy-eligible patients, giving the field a potential new therapeutic direction.
Ask SkimNews
